Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung Cancer
Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.
Reports of the Demise of Chemotherapy Have Been Greatly Exaggerated
The expanding arsenal of targeted and immuno-oncology drugs has unalterably changed the landscape of systemic cancer treatment, but chemotherapy will remain critical for years if not decades to come.
2 Clarke Drive Cranbury, NJ 08512